Your browser doesn't support javascript.
loading
Exercising the Sanger Sequencing Strategy for Variants Screening and Full-Length Genome of SARS-CoV-2 Virus during Alpha, Delta, and Omicron Outbreaks in Hiroshima.
Ko, Ko; Takahashi, Kazuaki; Nagashima, Shintaro; E, Bunthen; Ouoba, Serge; Takafuta, Toshiro; Fujii, Yoshiki; Mimori, Michi; Okada, Fumie; Kishita, Eisaku; Ariyoshi, Kunie; Hussain, Md Razeen Ashraf; Sugiyama, Aya; Akita, Tomoyuki; Kuwabara, Masao; Tanaka, Junko.
Afiliación
  • Ko K; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
  • Takahashi K; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
  • Nagashima S; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
  • E B; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
  • Ouoba S; Payment Certification Agency, Ministry of Health, Lot 80, Street 289, Sangkat Boeng Kak Ti Pir, Khan Tuol Kouk, Phnom Penh 12152, Cambodia.
  • Takafuta T; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
  • Fujii Y; Unité de Recherche Clinique de Nanoro (URCN), Nanoro BP18, Burkina Faso.
  • Mimori M; Hiroshima City Funairi Citizens Hospital, 14-11, Funairisaiwaicho, Naka-ku, Hiroshima 730-0844, Japan.
  • Okada F; Hiroshima City Institute of Public Health, 4 Chome-1-2, Shoko Center, Nishi-ku, Hiroshima 733-0833, Japan.
  • Kishita E; Hiroshima City Health and Welfare Bureau, 1 Chome-6-34, Kokutaijimachi, Naka-ku, Hiroshima 734-0042, Japan.
  • Ariyoshi K; Hiroshima Prefectural Health and Welfare Bureau, 10-52, Motomachi, Naka-ku, Hiroshima 730-8511, Japan.
  • Hussain MRA; Hiroshima Prefectural Health and Welfare Bureau, 10-52, Motomachi, Naka-ku, Hiroshima 730-8511, Japan.
  • Sugiyama A; Hiroshima Prefectural Technology Research Institute, Public Health and Environment Center, 1 Chome-6-29, Minamimachi, Minami-ku, Hiroshima 734-0007, Japan.
  • Akita T; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
  • Kuwabara M; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
  • Tanaka J; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Viruses ; 14(4)2022 03 30.
Article en En | MEDLINE | ID: mdl-35458450
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Japón